tldrdailynews.com logo

Lilly's Zepbound and Taltz Combo Shows Promise for Psoriatic Arthritis and Obesity

1 min read
Source: Eli Lilly
TL;DR

Eli Lilly's Phase 3b trial shows that combining Taltz (ixekizumab) and Zepbound (tirzepatide) significantly improves outcomes in adults with psoriatic arthritis and obesity, meeting primary and secondary efficacy endpoints and suggesting a potential new integrated treatment approach.

Topics:businesshealth#clinical-trial#health#obesity#psoriatic-arthritis#taltz#zepbound
Share this article
  1. Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight  Eli Lilly
  2. Lilly touts promise of Zepbound-Taltz combo in patients with obesity and psoriatic arthritis  Fierce Pharma
  3. Eli Lilly’s Zepbound, on top of immunology drug, helped reduce psoriatic arthritis symptoms  statnews.com
  4. Weight Loss Drugs Like Zepbound Could Help Treat Arthritis, Trial Shows  Gizmodo
  5. Lilly’s Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial  Reuters

Want the full story? Read the original reporting

Read on Eli Lilly